Condition: Graft Failure · Poor Graft Function · Sponsor: NYU Langone Health
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
This description comes directly from the study's public registry record.
Kiselle Mangalindan · 646-501-2973 · KiselleAnne.Mangalindan@nyulangone.org
Kelsey Stocker · 646-501-4848 · Kelsey.Stocker@nyulangone.org
Always discuss trial participation with your own doctor first.
| NYU Langone Health | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06569082